Neu Ulm

Researchers are evaluating how well insulin icodec helps people with type 1 diabetes control their blood sugar levels. This study focuses on participants who have never used insulin icodec before and aims to observe their treatment experience over a period of about 22 to 30 weeks. The study is designed as a real-world, multi-center, prospective observational study to assess glycemic control, treatment satisfaction, and adherence. Participants will be treated with commercially available insulin icodec as prescribed by their doctors, following usual clinical practice. There is no randomization or placebo group; all participants receive insulin icodec. The treatment period lasts approximately 22 to 30 weeks, during which participants continue their daily basal and bolus insulin regimen prior to starting insulin icodec. During the study, participants will have their blood sugar control monitored, including measuring changes in glycated hemoglobin (HbA1c) from baseline to week 26. Researchers will also assess treatment satisfaction and adherence. Participants must provide consent and be available for study visits and data recording throughout the study duration.

This research aims to assess how satisfied people with Multiple Sclerosis (MS) are after receiving subcutaneous (under the skin) injections of ocrelizumab over a period of 12 months. The study focuses on participants diagnosed with relapsing-remitting MS (RMS) or primary progressive MS (PPMS) according to 2017 McDonald criteria, who are starting ocrelizumab treatment for the first time. The main goal is to understand participant satisfaction using a special questionnaire designed for subcutaneous therapy administration. Participants will receive ocrelizumab as an injection under the skin, with the exact dosing and schedule determined by their treating physician following local medical guidelines. This observational study does not change standard care but monitors patients throughout their treatment with ocrelizumab. During the study, participants will complete the Therapy Administration Satisfaction Questionnaire for subcutaneous treatment after 12 months to measure their satisfaction. Researchers will also observe and record any relevant clinical information. The total study duration for each participant is 12 months, during which their experience and outcomes with ocrelizumab are carefully tracked.

Researchers are evaluating the safety, tolerability, and effects of AZD9550 alone and in combination with AZD6234 in people who are overweight or living with obesity, with or without type 2 diabetes (T2DM). This Phase I/II study includes participants aged 18 to 65 years for most parts and up to 75 years in some parts. The study aims to understand how AZD9550 is absorbed, distributed, and eliminated in the body and to assess safety when given alone or with AZD6234, especially in those with T2DM and obesity or overweight. The study is divided into multiple parts with different dosing schedules: Parts A-D investigate AZD9550 alone with doses increasing weekly or every few weeks; Part E studies the combination of AZD9550 and AZD6234 with increasing doses every 2 to 4 weeks; and Part F examines different ways to increase AZD9550 doses in participants without T2DM. Placebo injections matching the active treatments are used for comparison. Treatments are given as weekly subcutaneous injections. Participants will be closely monitored through various assessments including vital signs, ECGs, laboratory tests, and safety evaluations from screening until Day 261. Researchers will measure the number and percentage of participants experiencing adverse events, changes in lab or heart monitoring results, and the pharmacokinetics of AZD9550 such as concentration and elimination over time. The study also tracks tolerability and any treatment-related effects throughout the study duration.

Researchers are evaluating the safety, tolerability, immune response, and how the body processes and responds to different doses of M5542 when given under the skin in healthy adults aged 18 to 50. This Phase 1 study aims to understand these effects by administering single ascending doses of M5542 and comparing them to placebo in healthy participants. Participants will receive a single dose of either M5542 or a matching placebo subcutaneously on Day 1. The study will monitor participants closely after dosing to assess safety and immune responses. No additional treatment periods are described, focusing on this single-dose administration. During the study, participants will undergo medical evaluations, physical examinations, and laboratory tests to monitor for any adverse events, changes in vital signs, and other safety parameters up to Day 85. Researchers will measure immune responses and how the drug is processed in the body. The total study duration includes screening, dosing, and follow-up assessments over approximately 85 days.